A "Pheraplex" Capsule Labeled as Desoxymethyltestosterone From the Market Turned Out to Be 17,17-Dimethyl-18-nor-5α-androst-13-en-3β-ol.

IF 2.6 3区医学 Q2 BIOCHEMICAL RESEARCH METHODS

Drug Testing and Analysis Pub Date : 2025-05-23 DOI:10.1002/dta.3912

Sisi Zhu, Shan Wang, Xin Liu, Lisi Zhang

{"title":"A \"Pheraplex\" Capsule Labeled as Desoxymethyltestosterone From the Market Turned Out to Be 17,17-Dimethyl-18-nor-5α-androst-13-en-3β-ol.","authors":"Sisi Zhu, Shan Wang, Xin Liu, Lisi Zhang","doi":"10.1002/dta.3912","DOIUrl":null,"url":null,"abstract":"<p><p>In an effort to conduct a desoxymethyltestosterone (DMT) administration study to replenish excretion urine inventory of Beijing Anti-Doping Laboratory for quality assurance purpose, a product labeled as \"Pheraplex\" was purchased from the internet. The product's label indicated that each capsule contained 10 mg of 17α-methyl-etioallocholan-2-ene-17β-ol (DMT), along with medicinal corn starch and gelatin. To verify the product's contents, gas chromatography tandem quadrupole mass spectrometry (GC-MS/MS) was employed to analyze the active ingredient and compare it with the reference materials of DMT. Surprisingly, the results revealed that the product did not contain DMT or any other steroids monitored in the initial testing procedure of our laboratory. Subsequently, nuclear magnetic resonance was utilized to identify the compound's structure, which was determined to be 17,17-dimethyl-18-nor-5α-androst-13-en-3β-ol. This compound was referred to as M10 of 17α-methyltestosterone in a literature. This finding highlights the potential discrepancies between product labeling and actual contents in the supplement market, which deserves attention from the anti-doping community.</p>","PeriodicalId":160,"journal":{"name":"Drug Testing and Analysis","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Testing and Analysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/dta.3912","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

In an effort to conduct a desoxymethyltestosterone (DMT) administration study to replenish excretion urine inventory of Beijing Anti-Doping Laboratory for quality assurance purpose, a product labeled as "Pheraplex" was purchased from the internet. The product's label indicated that each capsule contained 10 mg of 17α-methyl-etioallocholan-2-ene-17β-ol (DMT), along with medicinal corn starch and gelatin. To verify the product's contents, gas chromatography tandem quadrupole mass spectrometry (GC-MS/MS) was employed to analyze the active ingredient and compare it with the reference materials of DMT. Surprisingly, the results revealed that the product did not contain DMT or any other steroids monitored in the initial testing procedure of our laboratory. Subsequently, nuclear magnetic resonance was utilized to identify the compound's structure, which was determined to be 17,17-dimethyl-18-nor-5α-androst-13-en-3β-ol. This compound was referred to as M10 of 17α-methyltestosterone in a literature. This finding highlights the potential discrepancies between product labeling and actual contents in the supplement market, which deserves attention from the anti-doping community.

查看原文本刊更多论文

市场上一种标记为脱氧甲基睾酮的“Pheraplex”胶囊原来是17,17-二甲基-18-no -5α-androst-13-en-3β-醇。

为了进行去氧甲基睾酮（DMT）给药研究，以补充北京反兴奋剂实验室的排泄尿液库存，以保证质量，从网上购买了一种标签为“Pheraplex”的产品。该产品的标签显示，每粒胶囊含有10毫克的17α-甲基-乙氧胆碱-2-烯-17β-醇（DMT），以及药用玉米淀粉和明胶。为了验证产品的含量，采用气相色谱-串联四极杆质谱（GC-MS/MS）对其有效成分进行分析，并与标准品DMT进行比较。令人惊讶的是，结果显示，该产品不含DMT或任何其他类固醇监测在我们实验室的初始测试程序。随后利用核磁共振对化合物结构进行鉴定，确定化合物为17,17-二甲基-18-no -5α-雄甾-13-en-3β-醇。该化合物在文献中被称为17α-甲基睾酮的M10。这一发现凸显了补充剂市场中产品标签与实际含量之间的潜在差异，值得反兴奋剂界的关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Testing and Analysis BIOCHEMICAL RESEARCH METHODS-CHEMISTRY, ANALYTICAL

CiteScore

5.90

自引率

24.10%

发文量

191

审稿时长

2.3 months

期刊介绍： As the incidence of drugs escalates in 21st century living, their detection and analysis have become increasingly important. Sport, the workplace, crime investigation, homeland security, the pharmaceutical industry and the environment are just some of the high profile arenas in which analytical testing has provided an important investigative tool for uncovering the presence of extraneous substances. In addition to the usual publishing fare of primary research articles, case reports and letters, Drug Testing and Analysis offers a unique combination of; ‘How to’ material such as ‘Tutorials’ and ‘Reviews’, Speculative pieces (‘Commentaries’ and ‘Perspectives'', providing a broader scientific and social context to the aspects of analytical testing), ‘Annual banned substance reviews’ (delivering a critical evaluation of the methods used in the characterization of established and newly outlawed compounds). Rather than focus on the application of a single technique, Drug Testing and Analysis employs a unique multidisciplinary approach to the field of controversial compound determination. Papers discussing chromatography, mass spectrometry, immunological approaches, 1D/2D gel electrophoresis, to name just a few select methods, are welcomed where their application is related to any of the six key topics listed below.